Special thanks to dr Pascale Chavassieux for performing the histomorphometric analysis of the bone biopsy.
99
References
1. Van Buchem F S, Hadders H N, Ubbens R. An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris. Acta radiol. 1955; 44:109-120.
2. Vanhoenacker FM, Balemans W, Tan GJ, Dikkers FG, De Schepper AM, Mathysen DG, Bernaerts A, Hul WV. Van Buchem disease: lifetime evolution of radioclinical features. Skeletal Radiol. 2003; 32:708-718.
3. Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, Brown A, Gardner JC, Galas D, Schatzman RC, Beighton P, Papapoulos S, Hamersma H, Brunkow ME. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002; 110:144-152.
4. Balemans W, Patel N, Ebeling M, Van HE, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, Foernzler D, Van HW. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002; 39:91-97.
5. van Bezooijen RL. SOST/Sclerostin: An Osteocyte-Derived Inhibitor of Bone Formation that Antagonizes Canonical Wnt Signaling. Bilezikian JP (ed.) Principles of Bone Biology, 3rd Edition, 2008; vol. 1. Academic Press. New York, NY, USA, pp. 139-152.
6. Balemans W, Ebeling M, Patel N, Van HE, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den EJ, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van HW. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10:537-543.
7. Brunkow ME, Gardner JC, Van NJ, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 68:577-589.
8. du Plessis JJ. Sclerosteosis: neurosurgical experience with 14 cases. J Neurosurg. 1993; 78:388-392. 9. Hamersma H, Gardner J, Beighton P. The natural history of sclerosteosis. Clin Genet. 2003;
63:192-197.
10. Marmary Y, Horne T, Azaz B. Hyperostosis corticalis generalisata: surgical management and long- term follow-up of one patient. Int J Oral Maxillofac Surg. 1989; 18:155-157.
11. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007; 18:1319-1328.
12. Weinstein RS. Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord. 2001; 2:65-73. 13. van Bezooijen RL, Roelen BA, Visser A, Wee-Pals L, de WE, Karperien M, Hamersma H,
100
Papapoulos SE, ten DP, Lowik CW. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004; 199:805-814.
14. van Bezooijen RL, Bronckers AL, Gortzak RA, Hogendoorn PC, Wee-Pals L, Balemans W, Oostenbroek HJ, Van HW, Hamersma H, Dikkers FG, Hamdy NA, Papapoulos SE, Lowik CW. Sclerostin in mineralized matrices and van Buchem disease. J Dent Res. 2009; 88:569-574. 15. Wergedal JE, Veskovic K, Hellan M, Nyght C, Balemans W, Libanati C, Vanhoenacker FM, Tan
J, Baylink DJ, Van HW. Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab. 2003; 88:5778-5783.
16. Lopez JM, Balemans W, Piters E, Van HW, Gonzalez G. Genetic analysis and effect of triiodothyronine and prednisone trial on bone turnover in a patient with craniotubular hyperostosis. Bone. 2008; 43:405-409.
17. Allen DT, Saunders AM, Northway WH, Jr., Williams GF, Schafer IA. Corticosteroids in the treatment of Engelmann’s disease: progressive diaphyseal dysplasia. Pediatrics. 1970; 46:523-531. 18. Janssens K, Vanhoenacker F, Bonduelle M, Verbruggen L, Van ML, Ralston S, Guanabens N,
Migone N, Wientroub S, Divizia MT, Bergmann C, Bennett C, Simsek S, Melancon S, Cundy T, Van HW. Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. J Med Genet. 2006; 43:1-11.
19. Minford AM, Hardy GJ, Forsythe WI, Fitton JM, Rowe VL. Engelmann’s disease and the effect of corticosteroids. A case report. J Bone Joint Surg Br. 1981; 63B:597-600.
20. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998; 102:274-282.
21. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 1999; 140:4382-4389.
22. Humphrey EL, Williams JH, Davie MW, Marshall MJ. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone. 2006; 38:652-661.
23. Vidal NO, Brandstrom H, Jonsson KB, Ohlsson C. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. J Endocrinol. 1998; 159:191-195. 24. Ogoshi T, Hagino H, Fukata S, Tanishima S, Okano T, Teshima R. Influence of glucocorticoid on
bone in 3-, 6-, and 12-month-old rats as determined by bone mass and histomorphometry. Mod Rheumatol. 2008; 18:552-561.
25. Bornefalk E, Dahlen I, Michaelsson K, Ljunggren, Ljunghall S. Age-dependent effect of oral Chapter 5
101
glucocorticoids on markers of bone resorption in patients with acute asthma. Calcif Tissue Int. 1998; 63:9-13.
26. Dovio A, Perazzolo L, Osella G, Ventura M, Termine A, Milano E, Bertolotto A, Angeli A. Immediate fall of bone formation and transient increase of bone resorption in the course of high- dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab. 2004; 89:4923-4928.
27. Gram J, Junker P, Nielsen HK, Bollerslev J. Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men. Bone. 1998; 23:297-302.
28. Kuroki Y, Kaji H, Kawano S, Kanda F, Takai Y, Kajikawa M, Sugimoto T. Short-term effects of glucocorticoid therapy on biochemical markers of bone metabolism in Japanese patients: a prospective study. J Bone Miner Metab. 2008; 26:271-278.
29. Paglia F, Dionisi S, De GS, Rosso R, Romagnoli E, Raejntroph N, Ragno A, Celi M, Pepe J, D’Erasmo E, Minisola S. Biomarkers of bone turnover after a short period of steroid therapy in elderly men. Clin Chem. 2001; 47:1314-1316.
30. Pearce G, Tabensky DA, Delmas PD, Baker HW, Seeman E. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab. 1998; 83:801-806.
31. Prummel MF, Wiersinga WM, Lips P, Sanders GT, Sauerwein HP. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab. 1991; 72:382-386.
32. Ton FN, Gunawardene SC, Lee H, Neer RM. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res. 2005; 20:464-470.
33. Frediani B, Falsetti P, Bisogno S, Baldi F, Acciai C, Filippou G, Bacarelli MR, Filipponi P, Galeazzi M, Marcolongo R. Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active rheumatoid arthritis: a 12-month randomized prospective controlled study. J Rheumatol. 2004; 31:1083-1087.
34. Hayashi K, Yamaguchi T, Yano S, Kanazawa I, Yamauchi M, Yamamoto M, Sugimoto T. BMP/ Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun. 2009; 379:261-266.
35. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum. 2008; 58:1674-1686.
36. Yun SI, Yoon HY, Jeong SY, Chung YS. Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3beta. J Bone Miner Metab. 2009; 27:140-148.
102
37. Fujita K Janz S. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer. 2007; 6:71- 38. Glass DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon
AP, Lang RA, Karsenty G. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005; 8:751-764.
39. Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci. 2006; 119:1283-1296.
40. Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL, Williams BO. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem. 2005; 280:21162-21168.